Data as of 3:59pm ET
| +0.14 / +2.23%|
The 4 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 9.53, with a high estimate of 10.25 and a low estimate of 4.99. The median estimate represents a +48.24% increase from the last price of 6.43.
The current consensus among 4 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.